Home / Drugs / Mavyret

Mavyret

Named-patient access overview. Mavyret is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

Quick orientation

Mavyret (glecaprevir / pibrentasvir) is an oral pangenotypic fixed-dose combination direct-acting antiviral developed by AbbVie that pairs an NS3/4A protease inhibitor with an NS5A inhibitor. The US Food and Drug Administration approved Mavyret in August 2017 for the treatment of chronic hepatitis C virus infection in adults and, after a 2021 pediatric expansion, in patients three years and older across all six major HCV genotypes. The drug is given as three oral tablets once daily with food, for an 8-week course in treatment-naive patients without cirrhosis and 12 to 16 weeks in select treatment-experienced or compensated-cirrhotic populations. Mavyret is prescribed and monitored by hepatology, gastroenterology, or infectious-disease specialists in outpatient liver-clinic settings.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Mavyret

  1. Patient or treating physician submits an intake at the patient portal.
  2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific named-patient documentation is prepared.
  5. Mavyret is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Mavyret in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Mavyret in Abu DhabiFull deep-dive on regulatory pathway, costs, timing Mavyret in BahrainFull deep-dive on regulatory pathway, costs, timing Mavyret in DubaiFull deep-dive on regulatory pathway, costs, timing Mavyret in KuwaitFull deep-dive on regulatory pathway, costs, timing Mavyret in OmanFull deep-dive on regulatory pathway, costs, timing Mavyret in PakistanFull deep-dive on regulatory pathway, costs, timing Mavyret in QatarFull deep-dive on regulatory pathway, costs, timing Mavyret in Saudi ArabiaFull deep-dive on regulatory pathway, costs, timing Mavyret in UAEFull deep-dive on regulatory pathway, costs, timing

Start a request for Mavyret

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp

About Mavyret

Anti-infective (Chronic HCV, all genotypes)
Manufacturer: AbbVie
Modality: oral pangenotypic direct-acting antiviral fixed-dose combination
Generic: glecaprevir / pibrentasvir

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides

WhatsApp
WhatsApp